JP2002500181A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002500181A5 JP2002500181A5 JP2000527236A JP2000527236A JP2002500181A5 JP 2002500181 A5 JP2002500181 A5 JP 2002500181A5 JP 2000527236 A JP2000527236 A JP 2000527236A JP 2000527236 A JP2000527236 A JP 2000527236A JP 2002500181 A5 JP2002500181 A5 JP 2002500181A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- riluzole
- per day
- composition according
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 9
- 229960004181 riluzole Drugs 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 208000012661 Dyskinesia Diseases 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 2
- 230000000561 anti-psychotic effect Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL12288398A IL122883A0 (en) | 1998-01-09 | 1998-01-09 | Pharmaceutical compositions for the treatment of dyskinesias |
| IL122883 | 1998-01-09 | ||
| IL127102 | 1998-11-17 | ||
| IL12710298A IL127102A0 (en) | 1998-11-17 | 1998-11-17 | Pharmaceutical compositions for the treatment of dyskinesias |
| PCT/IL1999/000003 WO1999034785A2 (en) | 1998-01-09 | 1999-01-05 | Treatment of dyskinesias |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002500181A JP2002500181A (ja) | 2002-01-08 |
| JP2002500181A5 true JP2002500181A5 (enExample) | 2006-03-02 |
Family
ID=26323572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000527236A Pending JP2002500181A (ja) | 1998-01-09 | 1999-01-05 | ジスキネジーの処置 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1043996A2 (enExample) |
| JP (1) | JP2002500181A (enExample) |
| KR (1) | KR20010033978A (enExample) |
| CN (1) | CN1290166A (enExample) |
| AU (1) | AU1780699A (enExample) |
| BR (1) | BR9906821A (enExample) |
| CA (1) | CA2317811A1 (enExample) |
| NO (1) | NO20003529L (enExample) |
| PL (1) | PL342098A1 (enExample) |
| WO (1) | WO1999034785A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2790670A1 (fr) * | 1999-03-12 | 2000-09-15 | Aventis Pharma Sa | Association riluzole et antagoniste des recepteurs ampa |
| JP2002539162A (ja) * | 1999-03-12 | 2002-11-19 | アベンテイス・フアルマ・ソシエテ・アノニム | リルゾールおよびａｍｐａ受容体アンタゴニストの組み合わせ剤を用いる筋萎縮性側索硬化症の治療 |
| FR2801793B1 (fr) * | 1999-12-01 | 2003-07-04 | Aventis Pharma Sa | Association d'une ergoline et de riluzole et son utilisation comme medicament |
| US6297254B1 (en) | 1999-12-01 | 2001-10-02 | Aventis Pharma S. A. | Method for the prevention or treatment of a motoneuron disease |
| FR2809620B1 (fr) * | 2000-06-05 | 2002-08-02 | Aventis Pharma Sa | Utilisation du riluzole ou ses sels pour la prevention et le traitement de l'adrenoleucodystrophie |
| ATE246919T1 (de) * | 2001-05-08 | 2003-08-15 | Sanol Arznei Schwarz Gmbh | Verbessertes transdermales therapeutisches system zur behandlung von morbus parkinson |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2688138B1 (fr) * | 1992-03-06 | 1995-05-05 | Rhone Poulenc Rorer Sa | Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique. |
| FR2700117B1 (fr) * | 1993-01-07 | 1995-02-03 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens. |
-
1999
- 1999-01-05 WO PCT/IL1999/000003 patent/WO1999034785A2/en not_active Ceased
- 1999-01-05 PL PL99342098A patent/PL342098A1/xx unknown
- 1999-01-05 KR KR1020007007567A patent/KR20010033978A/ko not_active Withdrawn
- 1999-01-05 JP JP2000527236A patent/JP2002500181A/ja active Pending
- 1999-01-05 EP EP99900116A patent/EP1043996A2/en not_active Withdrawn
- 1999-01-05 CN CN99802790A patent/CN1290166A/zh active Pending
- 1999-01-05 BR BR9906821-4A patent/BR9906821A/pt not_active IP Right Cessation
- 1999-01-05 AU AU17806/99A patent/AU1780699A/en not_active Abandoned
- 1999-01-05 CA CA002317811A patent/CA2317811A1/en not_active Abandoned
-
2000
- 2000-07-07 NO NO20003529A patent/NO20003529L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004056337A3 (en) | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats | |
| YU37301A (sh) | Farmaceutski preparat za modifikovano oslobađanje sensitizera insulina i drugog antidijabetskog agensa | |
| JO2555B1 (en) | Forms of oral doses of propiferine or pharmaceutically acceptable salts thereof with an extended release of active agent | |
| NZ514574A (en) | Novel method of treatment | |
| WO2001019337A3 (en) | Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing | |
| AU2277101A (en) | Stable extended release oral dosage composition | |
| AU2001283563A1 (en) | Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent | |
| AU7375598A (en) | Stable oral pharmaceutical dosage forms | |
| AU2276801A (en) | Extended release oral dosage composition | |
| JP2002511411A5 (enExample) | ||
| PL348734A1 (en) | New sustained release oral formulations | |
| AU7001001A (en) | Modified forms of pharmacologically active agents and uses therefor | |
| YU14502A (sh) | Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva | |
| AU1724301A (en) | Hydrogel-driven layered drug dosage form | |
| WO2000078294A3 (de) | Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac | |
| AU9018898A (en) | Phosphazole-containing nucleoside analogs, related compounds, pharmaceutical compositions thereof, and their use in in vitro medicinal treatments | |
| GEP20063882B (en) | Dosage regimen and pharmaceutical composition for emergency contraception | |
| AU2003238221A1 (en) | Ibuprofen suspension | |
| CA2325739A1 (en) | Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator | |
| WO2006004449A3 (en) | A combination composition | |
| BR0112847A (pt) | Uso de uma forma de dosagem sólida | |
| JP2002522501A5 (enExample) | ||
| CA2283255A1 (en) | Use of r-nsaid's for the prevention of alzheimer's disease | |
| JP2001513504A5 (enExample) | ||
| JP2002500181A5 (enExample) |